A brain signal linked to disease can be easy to see in large clumps, yet nearly impossible to identify when it is quietly doing its normal work. This study found a way to separate that healthy signal from misleading noise.

These disorders are marked by clumps inside brain cells called Lewy bodies. The clumps are mainly made of alpha-synuclein, a protein, and much of it carries a phosphate tag at one particular position when it has clumped together.

That tagged form is used as a sign of disease, but the usual detection tools also attach to other proteins in healthy brains. The result is a blurred signal that makes normal tagged alpha-synuclein hard to identify. The goal was to create a way to detect the body’s own, normal tagged alpha-synuclein while producing very little unrelated signal.

That matters because a useful brain measurement needs high specificity and low background when detecting the body’s own physiologically relevant tagged alpha-synuclein. The central idea is like checking whether two specific pieces of mail are in the same mailbox: a visible signal appears only when two matching markers come close together.

One marker recognizes alpha-synuclein itself, while the other recognizes its phosphate tag, so the assay tests the protein and its modification together. Requiring both markers to agree helps limit misleading signals, including cross-reactivity and background from markers that attach to unrelated proteins.

The ordinary detection tools were tested in nerve cells that either contained alpha-synuclein or did not. Several tools aimed at the phosphate tag produced extensive staining in both kinds of cells. That meant they were also recognizing other targets.

By contrast, the tool aimed at total alpha-synuclein stained only cells that actually contained the protein. With the two-marker approach, the signal specifically appeared in cultured nerve cells and another cultured human cell type. It detected the body’s own normal levels of tagged alpha-synuclein.

So the method could find the quiet, naturally occurring tagged signal, detecting endogenous physiological levels in both types of cultured cells. The combined staining marks the modified form of alpha-synuclein across several brain regions, while it largely disappears in animals unable to make alpha-synuclein.

Using either antibody alone does not produce the same specific pattern, supporting that the signal requires both to recognize the same target. The method also found tagged alpha-synuclein in human brain tissue from people without neurological disease and from people with dementia with Lewy bodies.

But the method did not readily reveal the densely packed Lewy bodies themselves in human tissue from dementia with Lewy bodies. The same failure remained when researchers changed one marker, using four B twelve for total alpha-synuclein together with R thirteen on human dementia with Lewy bodies tissue.

One possible reason is that long-standing, tightly packed clumps have a different structure or different chemical changes from the shorter-term clumps produced in animal models. Overall, the method reduces misleading signals and specifically detects normal, non-aggregated tagged alpha-synuclein in cultured cells, mouse brain tissue, and human brain tissue.

It can also detect increased levels in cell cultures and mouse models, but it does not stain Lewy bodies in human disease tissue. For patients and families, that means a clearer tool for asking what this protein is doing in healthy and diseased brain cells, while a separate test is still needed to find the dense disease clumps themselves.

The method specifically detects normal, soluble phosphorylated alpha-synuclein in cells and brain tissue, but misses the dense human disease clumps called Lewy bodies. That makes it useful for studying biology, not yet a complete disease detector.